dangers of glp 1 Exploring the Side Effects GLP-1 Receptor Agonist: To Ensure Its Optimal Positioning INFOGRAPHIC: The Hidden Risks of
Description
Mechanism of Action 17.4.9
We performed 1:1 propensity score matching (PSM) to generate comparable cohorts
Rather than targeting any single substance, GLP-1s appear to reduce the underlying craving mechanism itself
Stimulation of glucagon-like peptide-1 secretion by muscarinic agonist in a murine intestinal endocrine cell line
The trial currently has almost 10,000 patients enrolled and is expected to assess a composite MACE endpoint consisting of cardiovascular (CV) death, non-fatal myocardial infarction, or non-fatal stroke in patients with T2D as is expected to readout in July 2024 (NCT03574597)
